Walethmade%2525252525252525252525252525252525252525252525252525252525252525252525252525252520bromide

# Walethmade bromide ## Overview **Note:** There is no drug known as "Walethmade bromide" in clinical pharmacology databases. It is highly likely this is a misspelled or truncated query (possibly referencing *Aclidinium bromide*, *Tiotropium bromide*, or *Glycopyrrolate*). If this was intended to refer to a specific agent, please verify the name. This information pertains to common quaternary ammonium anticholinergics that share similar pharmacological nomenclature. ## Primary Indications Typically used for the management of chronic obstructive pulmonary disease (COPD) or the treatment of excessive secretions/sialorrhea. ## Adult Dosing Standard dosing for long-acting anticholinergic bronchodilators: * **Inhalation:** Usually 400 mcg via dry powder inhaler twice daily. * **Maximum:** 800 mcg/day. * *Note: Dosing is highly dependent on specific product formulation; consult local formulary.* ## Pediatric Dosing Not typically indicated for pediatric populations. Use is off-label and requires specialist guidance. Safety and efficacy not established in patients <18 years. ## Dose Adjustments * **Renal Impairment:** Generally unnecessary for inhaled anticholinergics due to minimal systemic absorption, but use caution in severe impairment. * **Hepatic Impairment:** No standard adjustments; however, monitor for systemic anticholinergic toxicity if systemic absorption occurs. ## Contraindications * Hypersensitivity to the drug or milk proteins (if contained in the carrier). * Acute treatment of bronchospasm or status asthmaticus (not an acute rescue medication). * Narrow-angle glaucoma (use with caution). * Urinary retention or prostatic hypertrophy. ## Adverse Effects * **Common:** Nasopharyngitis, headache, cough, sinusitis. * **Serious:** Paradoxical bronchospasm, urinary retention, narrow-angle glaucoma exacerbation, cardiac arrhythmias, and anaphylaxis. ## Key Drug Interactions * **Other Anticholinergics:** Concomitant use with ipratropium, tiotropium, or glycopyrrolate increases risk of additive systemic anticholinergic effects (e.g., dry mouth, constipation, tachycardia). * **CNS Depressants:** May have additive sedative effects. ## Monitoring * Monitor for paradoxical bronchospasm upon the first dose. * Assess for signs of urinary retention. * Evaluate changes in intraocular pressure if patient has a history of narrow-angle glaucoma. ## Clinical Pearls * **Administration:** Ensure patient technique is assessed to confirm medication reaches the lower airways. * **Classification:** These agents are quaternary ammonium compounds; they have poor systemic absorption following inhalation, which theoretically limits systemic side effects compared to tertiary amines (e.g., atropine). * **Inquiry:** If you intended to search for a different medication, please verify the spelling or the brand alias. *** **EDUCATIONAL DISCLAIMER:** This information is for educational purposes only and does not constitute medical advice. Please verify all dosages, contraindications, and drug interactions against the most current FDA-approved prescribing information or institutional clinical references before prescribing or administering medication.